{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:06:46Z","timestamp":1784286406302,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s41669-026-00650-1","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:10:47Z","timestamp":1776298247000},"page":"759-767","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Updated Health Economics Simulation Model of the Lifetime Progression of Multiple Sclerosis in an Australian Setting"],"prefix":"10.1007","volume":"10","author":[{"given":"Andrew J.","family":"Palmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-1930","authenticated-orcid":false,"given":"Ting","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Henson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasnat","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce V.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"van der Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"1","key":"650_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jns.2014.06.051","volume":"344","author":"MO Melcon","year":"2014","unstructured":"Melcon MO, Correale J, Melcon CM. Is it time for a new global classification of multiple sclerosis? J Neurol Sci. 2014;344(1):171\u201381.","journal-title":"J Neurol Sci"},{"issue":"3","key":"650_CR2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, Cutter GR, S\u00f8rensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis. Neurology. 2014;83(3):278\u201386.","journal-title":"Neurology"},{"key":"650_CR3","unstructured":"Campbell JA, Henson GJ, van der Mei I, Taylor BV. Multiple sclerosis prevalence and health economic impact in Australia 2025. 2025."},{"issue":"14","key":"650_CR4","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler J. 2020;26(14):1816\u201321.","journal-title":"Mult Scler J"},{"key":"650_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: OUP; 2006."},{"issue":"2","key":"650_CR6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40120-021-00264-1","volume":"10","author":"A Wiyani","year":"2021","unstructured":"Wiyani A, Badgujar L, Khurana V, Adlard N. How have economic evaluations in relapsing multiple sclerosis evolved over time? A systematic literature review. Neurol Ther. 2021;10(2):557\u201383.","journal-title":"Neurol Ther"},{"key":"650_CR7","volume-title":"Handbook of applied health economics in vaccines","author":"EF Drabo","year":"2023","unstructured":"Drabo EF, Padula WV. 264. Introduction to Markov modeling. In: Bishai D, Brenzel L, Padula W, editors. Handbook of applied health economics in vaccines. Oxford: Oxford University Press; 2023."},{"issue":"4","key":"650_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1177\/1352458519831213","volume":"26","author":"AJ Palmer","year":"2020","unstructured":"Palmer AJ, van der Mei I, Taylor BV, Clarke PM, Simpson S, Ahmad H. Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: evidence from Australia. Mult Scler J. 2020;26(4):411\u201320.","journal-title":"Mult Scler J"},{"issue":"9","key":"650_CR9","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin FD, H\u00e4ring DA, Ganjgahi H, Ocampo A, Hatami F, \u010cuklina J, et al. How patients with multiple sclerosis acquire disability. Brain. 2022;145(9):3147\u201361.","journal-title":"Brain"},{"issue":"2","key":"650_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s11136-022-03214-y","volume":"32","author":"JA Campbell","year":"2023","unstructured":"Campbell JA, Ahmad H, Chen G, van der Mei I, Taylor BV, Claflin S, et al. Validation of the EQ-5D-5L and psychosocial bolt-ons in a large cohort of people living with multiple sclerosis in Australia. Qual Life Res. 2023;32(2):553\u201368.","journal-title":"Qual Life Res"},{"issue":"1","key":"650_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12916-021-02204-0","volume":"20","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022;20(1):23.","journal-title":"BMC Med"},{"issue":"12","key":"650_CR12","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1592\/phco.28.12.1552","volume":"28","author":"S Kane-Gill","year":"2008","unstructured":"Kane-Gill S, Reddy P, Gupta SR, Bakst AW. Guidelines for pharmacoeconomic and outcomes research fellowship training programs: joint guidelines from the american college of clinical pharmacy and the international society of pharmacoeconomics and outcomes research. Pharmacotherapy. 2008;28(12):1552.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"650_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40273-024-01417-4","volume":"43","author":"JA Campbell","year":"2025","unstructured":"Campbell JA, Henson GJ, Ngwa VF, Ahmad H, Taylor BV, van der Mei I, et al. Estimation of transition probabilities from a large cohort (> 6000) of Australians living with multiple sclerosis (MS) for changing disability severity classifications, MS phenotype, and disease-modifying therapy classifications. Pharmacoeconomics. 2025;43(2):223\u201339.","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"650_CR14","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1007\/s11136-023-03486-y","volume":"32","author":"H Ahmad","year":"2023","unstructured":"Ahmad H, Campbell JA, van der Mei I, Taylor BV, Xia Q, Zhao T, et al. Estimating the disutility of relapse in relapsing\u2013remitting and secondary progressive multiple sclerosis using the EQ-5D-5L, AQoL-8D, EQ-5D-5L-psychosocial, and SF-6D: implications for health economic evaluation models. Qual Life Res. 2023;32(12):3373\u201387.","journal-title":"Qual Life Res"},{"key":"650_CR15","first-page":"101","volume":"29","author":"RJ Pokorski","year":"1997","unstructured":"Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med. 1997;29:101\u20136.","journal-title":"J Insur Med"},{"key":"650_CR16","unstructured":"Reserve Bank of Australia [Available from: https:\/\/www.rba.gov.au\/calculator\/."},{"key":"650_CR17","unstructured":"Australian Bureau of Statistics. https:\/\/www.abs.gov.au\/statistics\/economy\/price-indexes-and-inflation\/consumer-price-index-australia."},{"key":"650_CR18","unstructured":"The Pharmacetical Benefits Advisory Committee Guidelines. https:\/\/pbac.pbs.gov.au\/section-3a\/3a-1-overview-and-rationale-of-economic-evaluation.html."},{"key":"650_CR19","unstructured":"Australian Bureau of Statistics. Life expectancy. Canberra: ABS; 2022-2024 [cited 2026 March 16]. https:\/\/www.abs.gov.au\/statistics\/people\/population\/life-expectancy\/latest-release."},{"issue":"8","key":"650_CR20","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1002\/hec.4281","volume":"30","author":"AJ Palmer","year":"2021","unstructured":"Palmer AJ, Campbell JA, de Graaff B, Devlin N, Ahmad H, Clarke PM, et al. Population norms for quality adjusted life years for the United States of America, China, the United Kingdom and Australia. Health Econ. 2021;30(8):1950\u201377.","journal-title":"Health Econ"},{"issue":"4-5","key":"650_CR21","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.autrev.2014.01.012","volume":"13","author":"R Milo","year":"2014","unstructured":"Milo R, Miller A. Revised diagnostic criteria of multiple sclerosis. Autoimmun Rev. 2014;13(4\u20135):518\u201324.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"650_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1212\/WNL.0b013e31829a3388","volume":"81","author":"A Scalfari","year":"2013","unstructured":"Scalfari A, Knappertz V, Cutter G, Goodin DS, Ashton R, Ebers GC. Mortality in patients with multiple sclerosis. Neurology. 2013;81(2):184\u201392.","journal-title":"Neurology"},{"issue":"10","key":"650_CR23","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Amato MP, Centonze D, Gallo P, Gasperini C, Inglese M, et al. Early use of high-efficacy disease\u2011modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. 2022;269(10):5382\u201394.","journal-title":"J Neurol"},{"issue":"9","key":"650_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-abn2.173","volume":"93","author":"R Wynford-Thomas","year":"2022","unstructured":"Wynford-Thomas R, Uzochukwu E, Harding K, Anderson V, Cauchi M, Willis M, et al. 129 Multiple sclerosis relapse patterns in a population-based cohort. J Neurol Neurosurg Psychiatry. 2022;93(9):e2.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"650_CR25","unstructured":"MSBase. https:\/\/www.msbase.org\/."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00650-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-026-00650-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00650-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T10:25:31Z","timestamp":1784283931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-026-00650-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["650"],"URL":"https:\/\/doi.org\/10.1007\/s41669-026-00650-1","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declared no potential conflicts of interest with respect to the research, authorship, and publication of this article.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that support the findings of this study are available from the corresponding author, AJP, upon reasonable request.","order":3,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication (from Patients\/Participants)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The code of this study is available from the corresponding author, AJP, upon reasonable request.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AJP is responsible for the overall content as guarantor. AJP conceived the idea, designed and programmed the TreeAge model, generated, identified, and retrieved input data, drafted the manuscript, and addressed reviewers\u2019 comments. TZ co-drafted the manuscript and helped to address reviewers\u2019 comments. GJH, HA, BVT, and IvdM contributed to the manuscript. IvdM was responsible for the data collection of the Australian MS Longitudinal Study. GJH, JAC, and AJP estimated the transition probabilities. JAC contributed to the conceptualisation of the study, generated, identified, and retrieved input data, and contributed to the writing of the manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}